Symbols / AMLX $17.52 -0.40% Amylyx Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
AMLX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Scroll to Statements
Market Cap 1.94B Enterprise Value 1.63B Income -144.74M Sales — Book/sh 2.78 Cash/sh 2.87
Dividend Yield — Payout 0.00% Employees 136 IPO — P/E — Forward P/E -14.30
PEG — P/S — P/B 6.31 P/C — EV/EBITDA -10.64 EV/Sales —
Quick Ratio 13.98 Current Ratio 14.27 Debt/Eq 1.95 LT Debt/Eq — EPS (ttm) -1.53 EPS next Y -1.23
EPS Growth — Revenue Growth — Earnings 2026-05-07 ROA -36.41% ROE -61.59% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 110.54M Shs Float 82.88M Short Float 13.92%
Short Ratio 13.56 Short Interest — 52W High 18.61 52W Low 4.20 Beta -0.21 Avg Volume 1.08M
Volume 626.26K Target Price $22.80 Recom Strong_buy Prev Close $17.59 Price $17.52 Change -0.40%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.80
Mean price target
2. Current target
$17.52
Latest analyst target
3. DCF / Fair value
$-10.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$17.52
Low
$19.00
High
$34.00
Mean
$22.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-25 reit HC Wainwright & Co. Buy → Buy $34
2026-03-19 main Guggenheim Buy → Buy $30
2026-03-04 main HC Wainwright & Co. Buy → Buy $34
2026-03-03 init Stifel — → Buy $21
2026-02-20 main B of A Securities Buy → Buy $19
2026-02-10 main HC Wainwright & Co. Buy → Buy $28
2025-11-07 main HC Wainwright & Co. Buy → Buy $20
2025-10-17 main Citigroup Buy → Buy $20
2025-10-16 main Baird Outperform → Outperform $19
2025-10-03 main B of A Securities Buy → Buy $16
2025-09-16 main Goldman Sachs Buy → Buy $20
2025-09-15 main Guggenheim Buy → Buy $25
2025-08-28 main B of A Securities Buy → Buy $14
2025-06-24 init Guggenheim — → Buy $17
2025-06-17 init Citigroup — → Buy $12
2025-05-14 main Mizuho Outperform → Outperform $8
2025-05-09 main HC Wainwright & Co. Buy → Buy $16
2025-05-07 up Leerink Partners Market Perform → Outperform $10
2025-04-07 up Mizuho Neutral → Outperform $7
2025-03-05 reit HC Wainwright & Co. Buy → Buy $12
News
RSS: Latest AMLX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-05 BEDROSIAN CAMILLE L Officer — 95,990 $0.00 $0
2026-03-05 FRATES JAMES MATTHEW Chief Financial Officer — 95,990 $0.00 $0
2026-03-05 COHEN JOSHUA BARRY Chief Executive Officer — 248,865 $0.00 $0
2026-03-05 KLEE JUSTIN B Chief Executive Officer — 248,865 $0.00 $0
2026-03-05 MAZZARIELLO GINA Officer — 74,660 $0.00 $0
2026-03-02 BEDROSIAN CAMILLE L Officer — 6,461 $14.58 $94,205
2026-03-02 FRATES JAMES MATTHEW Chief Financial Officer — 7,909 $14.52 $114,851
2026-03-02 COHEN JOSHUA BARRY Chief Executive Officer — 29,282 $14.48 $424,120
2026-03-02 KLEE JUSTIN B Chief Executive Officer — 29,282 $14.47 $423,760
2026-03-02 MAZZARIELLO GINA Officer — 6,844 $14.52 $99,378
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
87.37
-77.06%
380.79
+1612.94%
22.23
Operating Revenue
0.00
-100.00%
87.37
-79.75%
431.43
+1491.77%
27.10
Cost Of Revenue
0.00
-100.00%
124.63
+389.89%
25.44
+750.02%
2.99
Reconciled Cost Of Revenue
0.00
-100.00%
124.63
+389.89%
25.44
+750.02%
2.99
Gross Profit
0.00
+100.00%
-37.26
-110.49%
355.35
+1747.20%
19.24
Operating Expense
153.29
-29.82%
218.41
-31.00%
316.54
+43.51%
220.58
Research And Development
90.40
-13.14%
104.08
-18.80%
128.19
+37.17%
93.45
Selling General And Administration
62.89
-45.00%
114.33
-39.30%
188.36
+48.16%
127.13
General And Administrative Expense
—
—
—
—
Other Gand A
—
—
—
—
Other Operating Expenses
—
—
—
—
Total Expenses
153.29
-55.31%
343.05
+0.31%
341.98
+52.96%
223.57
Operating Income
-153.29
+40.05%
-255.68
-758.93%
38.80
+119.27%
-201.34
Total Operating Income As Reported
-153.29
+51.29%
-314.73
-911.12%
38.80
+119.27%
-201.34
EBITDA
-152.77
+40.04%
-254.77
-738.69%
39.89
+119.86%
-200.85
Normalized EBITDA
-152.77
+21.95%
-195.72
-590.65%
39.89
+119.86%
-200.85
Reconciled Depreciation
0.53
-41.92%
0.90
-16.91%
1.09
+123.41%
0.49
EBIT
-153.29
+40.05%
-255.68
-758.93%
38.80
+119.27%
-201.34
Total Unusual Items
0.00
+100.00%
-59.05
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-59.05
0.00
—
Special Income Charges
0.00
+100.00%
-59.05
0.00
—
Other Special Charges
—
36.20
—
—
Restructuring And Mergern Acquisition
0.00
-100.00%
22.85
0.00
—
Net Income
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Pretax Income
-144.69
+52.11%
-302.14
-656.45%
54.30
+127.48%
-197.60
Net Non Operating Interest Income Expense
9.30
-32.64%
13.81
-14.52%
16.16
+276.49%
4.29
Interest Expense Non Operating
—
—
—
—
Net Interest Income
9.30
-32.64%
13.81
-14.52%
16.16
+276.49%
4.29
Interest Expense
—
—
—
—
Interest Income Non Operating
9.30
-32.64%
13.81
-14.52%
16.16
+276.49%
4.29
Interest Income
9.30
-32.64%
13.81
-14.52%
16.16
+276.49%
4.29
Other Income Expense
-0.70
+98.84%
-60.27
-9031.52%
-0.66
-19.78%
-0.55
Other Non Operating Income Expenses
-0.70
+42.34%
-1.21
-83.94%
-0.66
-19.78%
-0.55
Tax Provision
0.05
+111.70%
-0.39
-107.82%
5.03
+549.35%
0.77
Tax Rate For Calcs
0.00
-100.00%
0.00
-98.92%
0.00
-55.71%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.06
0.00
0.00
Net Income Including Noncontrolling Interests
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Net Income From Continuing Operation Net Minority Interest
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Net Income From Continuing And Discontinued Operation
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Net Income Continuous Operations
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Normalized Income
-144.74
+40.38%
-242.75
-592.68%
49.27
+124.84%
-198.38
Net Income Common Stockholders
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Diluted EPS
—
-4.43
-732.86%
0.70
+120.65%
-3.39
Basic EPS
—
-4.43
-706.85%
0.73
+121.53%
-3.39
Basic Average Shares
—
68.14
+1.35%
67.23
+14.94%
58.50
Diluted Average Shares
—
68.14
-2.64%
69.99
+19.65%
58.50
Diluted NI Availto Com Stockholders
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
332.64
+71.79%
193.63
-62.58%
517.45
+32.19%
391.45
Current Assets
323.67
+70.86%
189.43
-59.23%
464.67
+21.60%
382.13
Cash Cash Equivalents And Short Term Investments
316.98
+79.59%
176.50
-52.47%
371.36
+7.04%
346.94
Cash And Cash Equivalents
226.65
+192.86%
77.39
-54.53%
170.20
+172.21%
62.53
Other Short Term Investments
90.33
-8.86%
99.11
-50.73%
201.16
-29.27%
284.42
Receivables
0.09
-80.31%
0.45
-98.88%
40.05
+161.66%
15.31
Accounts Receivable
0.09
-80.31%
0.45
-98.88%
40.05
+161.66%
15.31
Inventory
—
0.00
-100.00%
38.32
+292.29%
9.77
Raw Materials
—
0.00
—
7.15
Work In Process
—
0.00
—
1.68
Finished Goods
—
0.00
—
0.94
Prepaid Assets
—
—
—
—
Current Deferred Assets
—
—
—
0.00
Other Current Assets
6.60
-47.10%
12.48
-16.39%
14.93
+47.64%
10.11
Total Non Current Assets
8.97
+113.56%
4.20
-92.04%
52.79
+466.39%
9.32
Net PPE
5.49
+100.99%
2.73
-57.39%
6.41
-21.19%
8.13
Gross PPE
7.04
+72.21%
4.09
-49.11%
8.04
-7.33%
8.68
Accumulated Depreciation
-1.55
-14.35%
-1.36
+16.52%
-1.63
-201.48%
-0.54
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.69
-12.06%
1.92
-45.82%
3.55
+63.40%
2.17
Construction In Progress
0.02
-91.40%
0.22
-62.48%
0.59
-26.65%
0.80
Other Properties
5.18
+192.55%
1.77
-52.46%
3.73
-32.57%
5.52
Leases
0.15
-12.50%
0.18
+0.00%
0.18
+0.00%
0.18
Other Non Current Assets
3.48
+136.94%
1.47
-96.83%
46.38
+3813.67%
1.19
Total Liabilities Net Minority Interest
27.39
-5.14%
28.87
-65.64%
84.02
+65.25%
50.85
Current Liabilities
22.69
-20.13%
28.41
-65.38%
82.04
+76.02%
46.61
Payables And Accrued Expenses
11.37
-32.68%
16.90
-73.18%
62.99
+114.72%
29.34
Payables
3.52
+19.73%
2.94
-86.68%
22.06
+252.58%
6.26
Accounts Payable
3.52
+19.73%
2.94
-86.68%
22.06
+252.58%
6.26
Other Payable
—
—
—
1.36
Current Accrued Expenses
7.86
-43.72%
13.96
-65.90%
40.93
+77.35%
23.08
Pensionand Other Post Retirement Benefit Plans Current
10.05
+0.63%
9.99
-40.49%
16.79
+10.24%
15.23
Current Debt And Capital Lease Obligation
1.26
-17.06%
1.52
-32.74%
2.26
+10.64%
2.04
Current Capital Lease Obligation
1.26
-17.06%
1.52
-32.74%
2.26
+10.64%
2.04
Other Current Liabilities
—
—
—
4.60
Total Non Current Liabilities Net Minority Interest
4.70
+914.69%
0.46
-76.62%
1.98
-53.27%
4.24
Long Term Debt And Capital Lease Obligation
4.70
+914.69%
0.46
-76.62%
1.98
-53.27%
4.24
Long Term Capital Lease Obligation
4.70
+914.69%
0.46
-76.62%
1.98
-53.27%
4.24
Tradeand Other Payables Non Current
—
—
—
—
Non Current Deferred Liabilities
—
—
—
0.00
Preferred Securities Outside Stock Equity
—
—
—
0.00
Stockholders Equity
305.26
+85.27%
164.76
-61.99%
433.43
+27.25%
340.61
Common Stock Equity
305.26
+85.27%
164.76
-61.99%
433.43
+27.25%
340.61
Capital Stock
0.01
+57.14%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+57.14%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
—
—
0.00
0.00
Share Issued
109.88
+60.11%
68.63
+1.36%
67.71
+1.80%
66.51
Ordinary Shares Number
109.88
+60.11%
68.63
+1.36%
67.71
+1.80%
66.51
Additional Paid In Capital
1,056.27
+36.90%
771.54
+4.52%
738.18
+6.23%
694.91
Retained Earnings
-751.43
-23.86%
-606.69
-98.95%
-304.95
+13.91%
-354.22
Gains Losses Not Affecting Retained Earnings
0.40
+539.13%
-0.09
-146.70%
0.20
+329.07%
-0.09
Other Equity Adjustments
0.40
+539.13%
-0.09
-146.70%
0.20
+329.07%
-0.09
Total Equity Gross Minority Interest
305.26
+85.27%
164.76
-61.99%
433.43
+27.25%
340.61
Total Capitalization
305.26
+85.27%
164.76
-61.99%
433.43
+27.25%
340.61
Working Capital
300.98
+86.92%
161.03
-57.92%
382.62
+14.04%
335.52
Invested Capital
305.26
+85.27%
164.76
-61.99%
433.43
+27.25%
340.61
Total Debt
5.96
+200.71%
1.98
-53.25%
4.24
-32.50%
6.28
Capital Lease Obligations
5.96
+200.71%
1.98
-53.25%
4.24
-32.50%
6.28
Net Tangible Assets
305.26
+85.27%
164.76
-61.99%
433.43
+27.25%
340.61
Tangible Book Value
305.26
+85.27%
164.76
-61.99%
433.43
+27.25%
340.61
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-123.34
+26.43%
-167.65
-1506.55%
11.92
+106.63%
-179.87
Cash Flow From Continuing Operating Activities
-123.34
+26.43%
-167.65
-1506.55%
11.92
+106.63%
-179.87
Net Income From Continuing Operations
-144.74
+52.03%
-301.74
-712.42%
49.27
+124.84%
-198.38
Depreciation Amortization Depletion
0.53
-41.92%
0.90
-16.91%
1.09
+123.41%
0.49
Depreciation
0.53
-41.92%
0.90
-16.91%
1.09
+123.41%
0.49
Depreciation And Amortization
0.53
-41.92%
0.90
-16.91%
1.09
+123.41%
0.49
Other Non Cash Items
-0.17
-100.45%
37.16
—
—
Stock Based Compensation
27.64
-16.32%
33.04
-11.09%
37.16
+71.14%
21.71
Asset Impairment Charge
0.00
-100.00%
118.68
0.00
—
Change In Working Capital
-1.08
+97.64%
-45.83
+30.20%
-65.66
-3901.28%
-1.64
Change In Receivables
0.38
-99.04%
39.96
+261.50%
-24.74
-66.97%
-14.82
Changes In Account Receivables
0.36
-99.09%
39.60
+260.05%
-24.74
-61.66%
-15.31
Change In Inventory
0.00
+100.00%
-9.25
+87.35%
-73.13
-648.58%
-9.77
Change In Prepaid Assets
3.98
+48.93%
2.67
+182.92%
-3.23
+38.21%
-5.22
Change In Payables And Accrued Expense
-6.02
+92.37%
-78.91
-310.55%
37.48
+34.30%
27.91
Change In Accrued Expense
-6.60
+88.97%
-59.81
-376.94%
21.60
-17.10%
26.05
Change In Payable
0.58
+103.04%
-19.10
-220.27%
15.88
+756.63%
1.85
Change In Account Payable
0.58
+103.04%
-19.10
-220.27%
15.88
+756.63%
1.85
Change In Other Current Assets
1.73
-11.46%
1.95
+24.62%
1.57
+32.99%
1.18
Change In Other Current Liabilities
-1.16
+48.49%
-2.26
-10.53%
-2.04
-122.57%
-0.92
Investing Cash Flow
14.04
-81.44%
75.65
-17.81%
92.05
+138.52%
-238.99
Cash Flow From Continuing Investing Activities
14.04
-81.44%
75.65
-17.81%
92.05
+138.52%
-238.99
Net PPE Purchase And Sale
-0.14
+12.10%
-0.16
+87.35%
-1.24
+50.87%
-2.53
Purchase Of PPE
-0.14
+12.10%
-0.16
+87.35%
-1.24
+50.87%
-2.53
Capital Expenditure
-0.14
+12.10%
-0.16
+87.35%
-1.24
+50.87%
-2.53
Net Investment Purchase And Sale
14.18
-87.34%
112.01
+20.07%
93.29
+139.45%
-236.46
Purchase Of Investment
-231.82
+0.07%
-231.99
+22.88%
-300.83
+27.66%
-415.87
Sale Of Investment
246.00
-28.49%
344.00
-12.72%
394.12
+119.67%
179.41
Net Other Investing Changes
—
-36.20
—
—
Financing Cash Flow
257.03
+73758.91%
0.35
-90.18%
3.54
-99.18%
431.79
Cash Flow From Continuing Financing Activities
257.03
+73758.91%
0.35
-90.18%
3.54
-99.18%
431.79
Net Issuance Payments Of Debt
—
—
0.00
0.00
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
—
—
0.00
0.00
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
—
—
0.00
0.00
Net Long Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
—
—
0.00
-100.00%
432.45
Proceeds From Stock Option Exercised
4.08
+91.23%
2.13
-69.52%
6.99
+219.51%
2.19
Net Other Financing Charges
252.95
+14278.92%
-1.78
+48.30%
-3.45
-21.22%
-2.85
Changes In Cash
147.72
+261.19%
-91.64
-185.24%
107.52
+731.52%
12.93
Effect Of Exchange Rate Changes
1.07
+345.21%
-0.44
-373.75%
0.16
+346.15%
-0.07
Beginning Cash Position
78.84
-53.87%
170.92
+170.25%
63.24
+25.54%
50.38
End Cash Position
227.64
+188.74%
78.84
-53.87%
170.92
+170.25%
63.24
Free Cash Flow
-123.48
+26.41%
-167.80
-1671.49%
10.68
+105.85%
-182.40
Income Tax Paid Supplemental Data
—
0.71
-88.92%
6.39
+23562.96%
0.03
Amortization Of Securities
-5.53
+43.93%
-9.86
+0.85%
-9.94
-383.46%
-2.06
Change In Interest Payable
—
—
0.00
0.00
Common Stock Issuance
—
—
0.00
-100.00%
432.45
Issuance Of Capital Stock
—
—
0.00
-100.00%
432.45
Net Preferred Stock Issuance
—
—
0.00
0.00
Preferred Stock Issuance
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category